This company listing is no longer active
Pfizer Management
Management criteria checks 3/4
Key information
Albert Bourla
Chief executive officer
US$24.4m
Total compensation
| CEO salary percentage | 6.93% |
| CEO tenure | 4.2yrs |
| CEO ownership | 0.007% |
| Management average tenure | 3.6yrs |
| Board average tenure | 6.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | n/a | n/a | US$31b |
| Oct 02 2022 | n/a | n/a | US$30b |
| Jul 03 2022 | n/a | n/a | US$29b |
| Apr 03 2022 | n/a | n/a | US$25b |
| Dec 31 2021 | US$24m | US$2m | US$22b |
| Oct 03 2021 | n/a | n/a | US$19b |
| Jul 04 2021 | n/a | n/a | US$12b |
| Apr 04 2021 | n/a | n/a | US$9b |
| Dec 31 2020 | US$21m | US$2m | US$7b |
| Sep 27 2020 | n/a | n/a | US$212m |
| Jun 28 2020 | n/a | n/a | US$7b |
| Mar 29 2020 | n/a | n/a | US$9b |
| Dec 31 2019 | US$18m | US$2m | US$11b |
| Sep 29 2019 | n/a | n/a | US$16b |
| Jun 30 2019 | n/a | n/a | US$13b |
| Mar 31 2019 | n/a | n/a | US$11b |
| Dec 31 2018 | US$10m | US$1m | US$4b |
| Sep 30 2018 | n/a | n/a | US$24b |
| Jul 01 2018 | n/a | n/a | US$23b |
| Apr 01 2018 | n/a | n/a | US$22b |
| Dec 31 2017 | US$9m | US$1m | US$21b |
| Oct 01 2017 | n/a | n/a | US$10b |
| Jul 02 2017 | n/a | n/a | US$8b |
| Apr 02 2017 | n/a | n/a | US$7b |
| Dec 31 2016 | US$9m | US$1m | US$7b |
Compensation vs Market: Albert's total compensation ($USD24.35M) is above average for companies of similar size in the Swedish market ($USD2.50M).
Compensation vs Earnings: Albert's compensation has been consistent with company performance over the past year.
CEO
Albert Bourla (60 yo)
Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and has been its Executive Director since February 23, 2018. Dr. Bourla was Chief Operating Officer...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 4.2yrs | US$24.35m | 0.0074% SEK 176.1m | |
| Chief Scientific Officer and President of Worldwide Research | 4.2yrs | US$10.91m | no data | |
| Executive VP & General Counsel | 9.3yrs | US$7.13m | 0.0032% SEK 77.1m | |
| Advisor | 1.6yrs | US$8.39m | 0.0054% SEK 129.2m | |
| Chief Commercial Officer & President of Global Biopharmaceuticals Business | 5.2yrs | US$9.03m | 0.0011% SEK 26.2m | |
| Chief Financial Officer & Executive VP | less than a year | no data | 0.000020% SEK 475.9k | |
| Senior VP | 3yrs | no data | 0.00019% SEK 4.5m | |
| Executive VP and Chief Digital & Technology Officer | 4.2yrs | no data | 0.00062% SEK 14.8m | |
| Senior VP & Chief Investor Relations Officer | 1.7yrs | no data | no data | |
| Executive VP and Chief Compliance | 9.3yrs | no data | 0.0016% SEK 37.6m | |
| Global Chief Marketing Officer | less than a year | no data | no data | |
| Chief People Experience Officer & Executive VP | 2.8yrs | no data | 0.00049% SEK 11.7m |
Experienced Management: PFE's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board & CEO | 5.1yrs | US$24.35m | 0.0074% SEK 176.1m | |
| Lead Independent Director | 9.5yrs | US$405.00k | no data | |
| Independent Director | 6.1yrs | US$345.00k | 0.00023% SEK 5.5m | |
| Independent Director | 15.5yrs | US$365.00k | 0.00018% SEK 4.3m | |
| Independent Director | 8.8yrs | US$365.00k | 0.000060% SEK 1.4m | |
| Member of Emerging Markets Advisory Board | no data | no data | no data | |
| Independent Director | 3yrs | US$339.35k | no data | |
| Independent Director | 5yrs | US$350.90k | no data | |
| Independent Director | 3.1yrs | US$355.00k | no data | |
| Independent Director | 3.8yrs | US$365.00k | 0.000070% SEK 1.7m | |
| Independent Director | 7.8yrs | US$365.00k | no data | |
| Independent Director | 11.3yrs | US$385.00k | no data |
Experienced Board: PFE's board of directors are considered experienced (6.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/02 19:52 |
| End of Day Share Price | 2023/02/28 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pfizer Inc. is covered by 43 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |